1001 results about "Differential diagnosis" patented technology

The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to rule in or out SIRS, or for differentiating sepsis, severe sepsis, septic shock and / or MODS from each other and / or from non-infectious SIRS.

An automated medical diagnostic system and method are disclosed. In an embodiment of the system and method, a matrix of cells is displayed via a graphical user interface on a computing device, each cell being representative of a patient health item (PHI) associated with a particular disease. A PHI is entered on the display in one of the cells and a differential diagnosis is updated based on the input PHI. The updated differential diagnosis is then displayed to a user. The system includes multiple diagnostic functions that use the matrix for input and output, wherein the diagnostic functions are selectively executed according to each newly input PHI so as to result in the differential diagnosis. In certain embodiments, the input PHIs are stored in a patient medical record. The computing device can operate independently or in a connection with a system server.

This method and apparatus for automated differential diagnosis of illness utilizes neural network technology to analyze information that has been collected and assimilated from multiple sources, including information concerning lifestyle and travel habits, occupational and environmental risks and other contributory factors, and compares this information to, and incorporates it into, databases, to render diagnoses as well as alerts regarding anomalous concentrations of illnesses. The invention has similar application in the area of mechanical maintenance and repair.

In a method for diagnosis and treatment of a patient with a tumor relating to prostate cancer, the following steps are implemented. A differential diagnosis of prostate cancer versus prostatitis and / or BPH is conducted on a patient using a cost-effective diagnosis method. If prostate cancer is diagnosed in the patient using a cost-effective measurement method, a characteristic value for the tumor aggressiveness of the prostate cancer is determined. A watchful waiting treatment is implemented with the patient given a characteristic value below a predeterminable first limit value. The size and position of the tumor is determined using a cost-effective method given a characteristic value above the first limit value. A cost-effective ultrasonic theranosis or a conventional therapy is conducted for a size below a second predeterminable limit value. The presence of metastases in the patient is checked, with a cost-intensive method generating image information, for a size above the second limit value. A metastasis treatment is implemented in the event that metastases are present. In the event that no metastases are present, a tumor treatment based on the aforementioned image information generated is implemented.

The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to rule in or out SIRS, or for differentiating sepsis, severe sepsis, septic shock and / or MODS from each other and / or from non-infectious SIRS.

The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to rule in or out SIRS, or for differentiating sepsis, severe sepsis, and / or septic shock from each other and / or from non-infectious SIRS.

The present invention relates to the field of the diagnosis of large intestine diseases. More particularly, embodiments of the invention provide a method for differential diagnosis of colorectal cancer from a non-malignant disease of the large intestine, and from a healthy large intestine.

The invention discloses micro ribonucleic acids (microRNA, miRNA) carried by cell microparticles (Microparticle, MP), a method for preparing the same, and application thereof in the technical field of biotechnological pharmacy. The invention provides a combination of the micro ribonucleic acids for evaluating the physiological and / or pathological states of a participant, and the combination contains all the micro ribonucleic acids which exist stably in serum / plasma particles of the participant and are detectable. At the same time, the invention provides an experimental method for preparing the cell microparticles containing specific micro ribonucleic acids and using the cell microparticles to perform gene-level regulation and control as well as modification on other cells and tissues. The combination and the method can be used for detecting and treating various diseases, including the aspects of the diagnosis and the differential diagnosis of various tumors, various acute and chronic infectious diseases and other acute and chronic diseases, the prediction and the curative effect evaluation of the occurrences of disease complications and the recurrences of malignant diseases, as well as the active ingredient screening, the efficacy evaluation and the judicial authentication of drugs, the detection of prohibited drugs and the like; besides, the combination and the method have the advantages of wide detection pedigree, high sensitivity, low detection cost, convenient available material, easy storage of samples and the like.

A novel relationship between pancreatico-biliary secretion and autistic syndrome is disclosed. This relationship enables a novel therapy for the treatment of the symptoms of autistic syndromes, comprising the administration of a therapeutically effective, preferably intravenous, dose of secretin to an individual with autistic syndrome. The relationship further enables a differential diagnosis for autistic syndrome, comprising an analysis of an individual's blood and / or intestinal tissue for the presence of secretin and comparison of the level of secretin to known norms.

The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to the use of biomarkers, either individually or in combinations with one another to rule in or out diseases of the aorta and its branches, most particularly aortic aneurysm and / or aortic dissection, and for risk stratification in such conditions. Preferred markers include one or more of creatine kinase-BB (CK-BB), creatine kinase-MB (CK-MB), acidic calponin, basic calponin, B-type natriuretic peptide (BNP), NT-proBNP, proBNP, BNP79-108, BNP3-108, caldesmon, caspase-3, D-dimer, soluble elastin fragments, endothelial cell-selective adhesion molecule (ESAM), fibrillin-1, heart-type fatty acid binding protein, MMP-9, myeloperoxidase, myoglobin, smooth muscle myosin, smooth muscle myosin heavy chain, TIMP-1, free cardiac troponin I, complexed cardiac troponin I, free and complexed cardiac troponin I, free cardiac troponin T, complexed cardiac troponin T, and free and complexed cardiac troponin T, and preferred assays are configured to detect these markers.

The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to rule in or out venous thromboembolic disease, pulmonary embolism, and / or deep vein thrombosis, and for risk stratification in such conditions.

A computer-based system and method is disclosed which constructs medical histories by direct interactions between the patient and system that acquires pertinent and relevant medical information covering the complete life of a given patient. The system and method insure that a complete life long medical history is acquired from every patient interacting with the health care system. Once acquired, the facts of the patient's life long and family medical history are analyzed automatically by databases to generate a set of the most reasonable diagnostic possibilities (the differential diagnosis) for each medical problem identified and for each risk factor for disease that is uncovered in the historical database. Further, the automatically analyzed database of historical medical information is used as the search tool for bringing to bear, on the diagnosis and treatment of each medical problem identified in each patient, the entirety of medical knowledge that relates to and can be useful for the correct and efficient diagnosis and treatment of each of every patient's medical problems. This collection of information is analyzed to generate a final diagnosis and treatment regimen.

The present invention relates to pathogen detection and identification by use of DNA resequencing microarrays. The present invention also provides resequencing microarray chips for differential diagnosis and serotyping of pathogens present in a biological sample. The present invention further provides methods of detecting the presence and identity of pathogens present in a biological sample.

The present invention provides methods for the identification and use of diagnostic markers for differential diagnosis of diseases. In a various aspects, the invention relates to methods and compositions able to determine the presence or absence of one, and preferably a plurality, of diseases that exhibit one or more similar or identical symptoms. Such methods and compositions can be used to provide assays and assay devices for use in determining the disease underlying one or more non-specific symptoms exhibited in a clinical setting.

The present invention includes compositions, systems and methods for the early detection and consistent determination of the extent, type and nature of a host immune response and the nature of the infectious disease using gene expression data.

This invention is directed to a novel method to detect adenomas and colorectal cancer (CRC) using a bacterial signature. Included in the invention are methods of (a) determining an individual's risk developing adenomas or CRC; (b) determine whether or not a patient should have a colonoscopy; (c) differential diagnosis; (d) staging; (e) selecting therapies; (f) monitoring therapies; (g) patient surveillance; and (h) drug screening. Kits and reagents for detecting adenomas and CRC and / or drug screening are also part of the invention.

The invention relates to a marker for detecting colon and rectum cancer by utilizing 86 specific ribonucleic acids stably existing in the serum / plasma of a human body, as well as a method, a relevant kit and a biological chip for detecting the marker. The method can be used in the aspects of diagnosing and differentially diagnosing the colon and rectum cancer and predicting the generation and the recurrence of the complications of diseases, evaluating the curative effect, screening the active ingredients in drugs, evaluating the drug effect and the like, and has the advantages of wide detection pedigree, high sensitivity and low detection cost, material is convenient for obtainment, samples are easy to store and the like. The method can be widely used for generally surveying the colon and rectum cancer and relevant work and improving low specificity and low sensitivity which are brought by the individual difference difficultly and are difficult to overcome by the single marker, thereby obviously enhancing the clinical detection rate of the colon and rectum cancer and becoming an effective means for early diagnosing the colon and rectum cancer.

The invention provides a pancreatic cancer marker, and a detection method, a kit and a biochip thereof. The pancreatic cancer marker provided by the invention contains 36 kinds of micro ribonucleic acids which stably exist in the serum / plasma of a person receiving the test and can be detected. The invention also provides a kit and a biochip of tools or elements for detecting the pancreatic cancer marker. The combination, the method, the kit and the biochip provided by the invention can be used for auxiliary diagnosis and differential diagnosis of pancreatic cancers, predication of occurrence and recrudescence of disease complications, evaluation of the curative effect, screening of active ingredients of medicaments, evaluation of pesticide effectiveness and the like, and has the advantages of wide detection range, high sensitivity, low detection cost, readily available raw materials, easy storage of samples and the like; and the method is widely applied to work related to the general survey of pancreatic cancers, improves the specificity and sensitivity which are low in the single marker due to individual difference, obviously increases clinical detection rate of pancreatic cancers and becomes an effective method for early diagnosis of pancreatic cancers.

An apparatus, software, procedures and technology that, beginning with a simple manipulative auditory paradigm, moves up the auditory neural pathways, modifying the basic stimulus from a unilateral routine audiology tool to a dichotic central auditory processing diagnostic tool that defines hearing loss along the entire auditory chain from the middle ear to the cortex. From the resultant data comes information related to the reduction of tinnitus employing parathreshold central procedures rather than the traditional suprathreshold masking or phase-shifting techniques. The new application modifies and applies known technology in new ways for both the top-down and bottom-up differential diagnosis of auditory disorders and the tinnitus reduction.

The present invention relates to an automated method for quality assurance (QA) which creates quality-centric data contained within a medical report, and uses these data elements to determine report accuracy and correlation with clinical outcomes. In addition to a QA report analysis, the present invention also provides an automated mechanism to customize report content base upon end-user preferences and QA feedback. In one embodiment, a computer-implemented method of automated medical QA includes storing QA data and supportive data in at least one database; identifying a QA discrepancy from QA data; assigning a level of clinical severity, to the QA discrepancy; creating an automated differential diagnosis based on the level of clinical severity, to determine clinical outcomes; and analyzing the QA data and correlating the analysis of the QA data with stored supportive data and clinical outcomes.

A method for diagnosing Alzheimer's disease(AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.

The invention discloses a test strip which is used for testing porcine viral diarrhea pathogen in one step, and the test strip comprises a support layer, an adsorption layer and a protection layer. The adsorption layer has a sample fiber layer, a gold antibody fiber layer, a cellulose film layer and a hygroscopic material layer at the handle end sequentially from a test end. The cellulose film layer has a test blot and a contrast blot, and the gold antibody fiber layer is adhered with at least one of monoclonal antibodies or polyclonal antibodies of anti-TGEV, anti-PDEV and anti-RV with colloid gold mark; the test blot is printed by at least one of polyclonal antibody liquid or monoclonal antibody liquid of anti-TGEV, anti-PDEV and anti-RV, and the contrast blot is printed by IgG solution of sheep or rabbit anti-mouse or IgG solution of sheet or rabbit anti-porcine. When used for testing, the test strip has the advantages of strong specificity, high sensitivity, convenient and rapid operation and direct and accurate testing result. The test strip is especially suitable for fast identifying and diagnosing on site.

Methods are provided for the prediction, diagnosis and differential diagnosis of Alzheimer's disease. More particularly, a method is provided to determine whether a subject that does not show any clinical signs of Alzheimer's disease has a likelihood to develop Alzheimer's disease. Further a method is provided for the diagnosis of subjects suffering from Alzheimer's disease and / or for the differential diagnosis of subjects suffering from Alzheimer's disease versus subjects suffering from other dementias such as dementia with Lewy bodies. The methods are based on the determination of the ratio of specific Aβ peptides.

An immunogenic or vaccine composition to induce an immune response or protective immune response against West Nile virus (WNV) in an animal susceptible to WNV. The composition includes a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector contains heterologous nucleic acid molecule(s), expresses in vivo in the animal WNV antigen, immunogen or epitope thereof, e.g., WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or WNV polyprotein prM-M-E. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.

The invention relates to an ELISpot tuberculosis infection diagnostic kit and the application, which adopts the genetic engineering technology to obtain a CFP10-ESAT6 fusion protein antigen from a mycobacterium tuberculosis by cloning, expression and purification, a tuberculosis specific cell stimulator is used for stimulating the peripheral blood T lymphocyte cell of the detected person to secrete a specific IFN-Gamma, then the invention is detected by ELISpot, and the whole process needs to take two days. The usage of the invention can be used for detecting whether the detected person is infected by mycobacterium tuberculosis by using the naked eye or instrument to determine the result according to the number of the generated purple blue spots, so as to assist the diagnosis of tuberculosis and differential diagnosis.

The present invention relates to new methods for the specific detection, quantification and / or differential diagnosis of neurodegeneration in an individual making use of a combination assay detecting at least three neurological markers in one or more body fluids of said individual, the type and degree of neurodegeneration being reflected in the quantitative changes in the level of all of said neurological markers compared to the control sample. The present invention also relates to methods for the detection of Rab3a, SNAP25 and alpha-synuclein in cerebrospinal fluid and to the use of these methods in a combination assay for specific detection, quantification and / or differential diagnosis of neurodegeneration.

Systems and methods for assessment of sleep quality in adults and children are provided. These techniques include an apparatus worn above the forehead containing the circuitry for collecting and storing physiological signals. The apparatus integrates with a sensor strip and a nasal mask to obtain the physiological signals for the user. The form factor of this apparatus is comfortable, easy to self-apply, and results in less data artifacts than conventional techniques for capturing physiological data for analyzing sleep quality. Neuro-respiratory signals are analyzed using means to extract more accurate definitions of the frequency and severity of sleep discontinuity, sleep disordered breathing and patterns of sleep architecture.; Biological biomarkers and questionnaire responses can also be compared to a database of healthy and chronically diseased patients to provide a more accurate differential diagnosis and to help determine the appropriate disease management recommendations.